Despite having great science and a proven ability to get drugs approved, Europe’s biotech ecosystem will remain in the shadows of the US as long as investors continue to adopt a risk-averse culture.
That was the key message to come out of a panel at BIO-Europe in Stockholm, Sweden (4-6 November), voiced most...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?